Last reviewed · How we verify
AD17002
At a glance
| Generic name | AD17002 |
|---|---|
| Also known as | LTh(αK) |
| Sponsor | Advagene Biopharma Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma (PHASE2)
- Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis (PHASE1, PHASE2)
- AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma (PHASE1, PHASE2)
- Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19 (PHASE2, PHASE3)
- Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD17002 CI brief — competitive landscape report
- AD17002 updates RSS · CI watch RSS
- Advagene Biopharma Co. Ltd. portfolio CI